PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.GlobeNewsWire • 11/04/24
PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024GlobeNewsWire • 06/07/24
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureusGlobeNewsWire • 04/15/24
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)GlobeNewsWire • 04/05/24
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketGlobeNewsWire • 03/11/24
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketGlobeNewsWire • 02/20/24
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024GlobeNewsWire • 01/18/24
PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusGlobeNewsWire • 10/24/23
TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendationGlobeNewsWire • 10/23/23
PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strainsGlobeNewsWire • 10/09/23
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial targetGlobeNewsWire • 09/19/23
PHAXIAM Therapeutics publishes its cash position and new financial calendar, and announces its participation at upcoming investor conferencesGlobeNewsWire • 09/05/23